Search the Newsreel

Polyrizon Ltd (PLRZ) Balance Sheet

This article provides the balance sheet for Polyrizon Ltd (PLRZ), offering both annual and quarterly financial data to assess the company's financial health. It details key metrics such as cash, assets, liabilities, and shareholders' equity over several fiscal periods, along with FAQs explaining important …

Olympia Financial Group Inc. Announces Sale of Raisr Division

Polymetals Resources Exchanges AU$28 Million Endeavor Mine Rehabilitation Bond; Shares Down 3%

Polyplex re-appoints Sanjay Gupta & Associates as cost auditor

Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Oncolytics Biotech Inc (ONCY) shareholder structure, detailing major individual and institutional holdings. It includes a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity. Key individual shareholders like Kirk J Look and Thomas …

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

PolyPid Ltd. and Azurity Pharmaceuticals have signed an exclusive deal worth up to US$330 million for the commercialization of D-PLEX100, an infection-prevention drug, in the U.S. and Canada. The agreement includes an upfront payment of US$15 million, potential milestone payments, and Azurity funding further …

TradingKey

This article provides an income statement overview for Polyrizon Ltd (PLRZ) on TradingKey, detailing both quarterly and annual financial performance. It explains how to interpret the income statement, highlights the difference between quarterly and annual data, defines 'YOY,' and lists key metrics for analyzing …

Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Polyrizon Ltd (PLRZ) using various indicators and moving averages. It details current buy, sell, and neutral signals for indicators like MACD, RSI, and KDJ, with a majority of moving averages (MA5 to MA200) showing buy signals. The …

PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880

This article provides an analysis of Polyrizon Ltd (PLRZ) through TradingKey's stock scoring system, although no score is available due to insufficient data. It details the methodology behind TradingKey's comprehensive stock assessment, explaining how financial health, valuation, earnings forecasts, price momentum, institutional confidence, and …

Olympia Financial Group Inc. Revenue Breakdown – TSX:OLY

PYPD|PolyPid Ltd|Price:3.900|Chg%:-0.340

PolyPid Ltd (PYPD) stock closed at $3.900, down 8.02% from its previous close. Analysts currently rate PYPD as a "Buy" with a target price of $12.00, suggesting a significant upside. The company is a biopharmaceutical firm focused on developing locally administered therapies for surgical …

Vardhman Jain Tijaria raises stake in Tijaria Polypipes to 4.33%

Gulshan Polyols confirms no UPSI shared in NDTV media interaction

Polygon Real Estate Ltd. Revenue Breakdown – TASE:POLY

Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Oncolytics Biotech (ONCY) received a notice from Nasdaq on July 20, 2026, indicating its failure to maintain the minimum $1.00 bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 days, until January 19, 2027, to regain compliance, …

Oncolytics Biotech gets Nasdaq notice for failing $1 minimum bid price rule

Oncolytics Biotech has received a Nasdaq notice due to its stock (ONCY) failing to maintain a $1 minimum bid price for 30 consecutive trading sessions. The company has been given a 180-day period, ending January 19, 2027, to regain compliance by having its stock …

ONCY Q2'26 Earnings: revenue estimate is 0 USD

Oncolytics Biotech Inc. (ONCY) is scheduled to release its Q2'26 earnings on July 31. The company is expected to report 0 USD in revenue and an EPS of (0.05) USD for the quarter. This article provides a brief overview of the upcoming earnings and …

PolyNovo (ASX:PNV) Plunges as Healthcare Stocks Join the Market Retreat

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD:NASDAQ) has entered into a commercialization agreement with Azurity Pharmaceuticals for its antibacterial drug, D-PLEX100, which aims to prevent surgical site infections. The deal provides PolyPid with an upfront payment of US$15 million, potential milestone payments up to US$300 million, and a …

H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13

H.C. Wainwright has reaffirmed its Buy rating for PolyPid (PYPD.US) and maintained its target price of $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

PolyNovo FY26 earnings: Record revenue and cash flow

HC Wainwright Has Optimistic Outlook of PolyPid Q2 Earnings

Polynovo (ASX:PNV) Slides Lower: Medtech Name Pulls Back Despite Broader Gains

Coppermoly (ASX:COY) Expands Portfolio With Wyemandoo Critical Minerals Acquisition

H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com

H.C. Wainwright has reiterated its Buy rating and $13 price target for PolyPid (NASDAQ:PYPD) following a significant licensing agreement. PolyPid entered an exclusive licensing and collaboration agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, which includes $30 million upfront/near-term and potential …

Nahar Poly Films Share Price Forecast: 3 Year Outlook to 2030

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid has announced an exclusive commercial partnership with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX₁₀₀, a drug designed to prevent surgical site infections. PolyPid stands to receive over $320 million in potential payments, including an initial $30 million upfront and near-term …

PolyPid - Eligible for up to $300 Mln in Addi

This article announces that PolyPid is eligible for up to $300 million in additional funding. The exact nature of this funding (e.g., grants, investments, milestone payments) is not detailed in the provided content. The brief title suggests a significant financial boost for the company.

PolyPid, Azurity sign surgical site infection drug deal

Israeli biotech PolyPid has signed a deal with Azurity Pharmaceuticals to commercialize its D-PLEX100 drug, aimed at preventing surgical site infections, in the U.S. and Canada. The agreement could bring PolyPid over $320 million, including an initial $15 million and potential milestone payments. PolyPid …

PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3

PolyPid has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for its D-PLEX100 product in the U.S. and Canada, aimed at preventing surgical site infections. The deal, valued at over $320 million, includes upfront payments, milestones, and royalties, building on positive Phase 3 …

PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada

PolyPid Ltd. announced an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100, aimed at preventing surgical site infections in the U.S. and Canada. The deal includes an upfront payment of $15 million, an additional $15 million upon FDA acceptance of the New Drug Application, …

Oncolytics' Pelareorep Gets Fast Track Designation In Second-Line And Later Anal Cancer; Stock Down

(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to Pelareorep in combination with a checkpoint inhibitor in second-Line and later Anal Cancer. The designation covers patients with …

Bhansali Engineering Polymers profit rises 43% to ₹65.6 crore

Rajshree Polypack wins ₹3.09 Cr order for plastic rigid sheets

Stocks in play: Oncolytics Biotech Inc

Oncolytics Biotech Inc (N.ONCY) has received Fast Track designation from the U.S. Food and Drug Administration for pelareorep combined with a checkpoint inhibitor. This designation is for treating inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal that has progressed on …

FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com

Oncolytics Biotech Inc. (NASDAQ: ONCY) has received Fast Track designation from the FDA for pelareorep combined with a checkpoint inhibitor to treat inoperable, recurrent, or metastatic anal canal squamous cell carcinoma. This designation accelerates development and review for therapies addressing serious diseases with unmet …